Navigation Links
Oramed Pharmaceuticals Presents Results of its Phase IIb Clinical Trial at the Diabetes Technology Meeting 2010 in Bethesda, MD
Date:11/15/2010

harmaceuticals Inc. (OTCBB: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, presented the results of its recently completed Phase IIb trial. The multicenter, placebo-controlled, randomized, double-blind study conducted in 29 patients with Type II diabetes assessed the safety of ORMD-0801 in patients with Type II diabetes. Results were presented by the company's Chief Scientific Officer, Dr. Miriam Kidron, at the Tenth Annual Meeting of the Diabetes Technology Society, in Bethesda, Maryland.

The poster presentation entitled "Extended exposure to an oral insulin formulation yields decreased insulin secretion in Type II diabetes subjects," described Oramed's first extended exposure study to its oral insulin product (ORMD-0801), where 21 patients were treated with ORMD-0801, self-administered daily for a period of six weeks. In parallel, a group of eight patients received placebo capsules administered under the same treatment regimen. ORMD-0801 proved safe and tolerable, with no reports of serious adverse events throughout the study. In addition, no cumulative effects of extended ORMD-0801 exposure were noted, and only two mild cases of transient hypoglycemia were reported. Treatment efficacy was evaluated via markers quantified from blood samples drawn at the start and end of the study. Daily administration of oral insulin led to a statistically significant decrease in both insulin and C-reactive protein (CRP) levels, in contrast to their elevation among placebo-treated individuals. Moreover, the percentage of subjects demonstrating clinically relevant reductions in insulin, c-peptide, fasting blood glucose (FBG) and Hb1Ac levels was consistently higher in the ORMD-0801 cohort, when compared to its placebo counterpart. This study addressing, for the first time, potential long-term safety concerns from extended ORMD-0801 administrations, demonstrated safety and no seri
'/>"/>

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Oramed Pharmaceuticals was Chosen to Present Two Abstracts at the 70th Scientific Sessions of the American Diabetes Association in Orlando, FL, June 25-29, 2010
2. Oramed Pharmaceuticals Announces Publication of Research Article on its Oral Insulin Capsule ORMD-0801 in Diabetes, Obesity and Metabolism
3. Oramed Pharmaceuticals Announces That Dr. Michael Berelowitz, Senior Vice President at Pfizer, Joins its Board of Directors
4. Oramed Pharmaceuticals Reports Results in Phase 2b Trial of Oral Insulin Administration to Type 2 Diabetes Patients
5. Orameds Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland
6. Oramed Pharmaceuticals Commences Human Clinical Trials of an Oral GLP-1 Analog
7. Oramed Pharmaceuticals to Present at Rodman & Renshaw 11th Annual Healthcare Conference
8. Frost and Sullivan Honors Oramed Pharmaceuticals With the 2009 European Oral Drug Delivery Technology Innovation Award
9. Oramed Pharmaceuticals was Awarded a NIS 3.1 Million Grant From the Israeli Office of the Chief Scientist
10. Oramed Pharmaceuticals Reports Positive Results From a Study of Oral Insulin Capsule on Type 1 Diabetic Patients
11. Oramed Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference (November 11, 2008; NYC)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014 With the accelerated aging ... health expenditure as well as the improved medical ... diagnostic reagent industry has been developing quickly, especially ... 2013, Chinese in vitro diagnostics market size reached ... in vitro diagnostic reagents. , Read complete ...
(Date:7/30/2014)... SAN DIEGO , July 30, 2014  Orexigen ... it has received the Day 180 List of Outstanding ... Medicinal Products for Human Use (CHMP) for the NB32 ... / bupropion SR) is an investigational drug candidate being ... of the earlier Day 120 time point were adequately ...
(Date:7/30/2014)... , July 30, 2014  RXi ... a biotechnology company focused on discovering, developing ... medical needs using RNA-targeted technologies, today announced ... with RXI-109, for the reduction of recurrence ... surgery, has been initiated. Logo ...
(Date:7/30/2014)... July 30, 2014 Immunology ... leading Immunologists, Principle Investigators, scientists in the field, ... Malemud, Professor at Case Western Reserve University School ... keynote address on “The effects of recombinant ... of matrix metalloproteinase-9”. Arya Biragyn, a Senior investigator ...
Breaking Biology Technology:China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5Unveiling Breakthroughs in Clinical & Cellular Immunology 2Unveiling Breakthroughs in Clinical & Cellular Immunology 3
... Oct. 1 Maven Biotechnologies today announced that the ... Institute for Allergy and Infectious Disease (NIAID), part of ... TM imaging technology for label-free protein microarrays and ... Maven through the federal stimulus package initiative for Biomedical ...
... The Culex quinquefasciatus mosquito poses a significant ... elephantiasis-causing worms and encephalitis-inducing viruses. An international team of ... the SIB Swiss Institute of Bioinformatics sequenced its genome ... published in today,s issue of Science, describe results from ...
... 1 Vet-Stem, Inc. announced that Dr. Robert Harman, ... entitled "Stem Cell Therapy: Mechanisms of Action" at the ... Surgeons (ACVS) in Seattle, WA, October 21, 2010.   ... http://www.newscom.com/cgi-bin/prnh/20060425/VETSTEMLOGO ) Dr. Harman has presented ...
Cached Biology Technology:Maven Biotechnologies Receives $1.96 Million From the National Institutes of Health (NIH) to Develop Their LFIRE™ Label-Free Detection Technology for Proteomics 2Major disease-vector mosquito reveals the secrets of its immune system 2Vet-Stem CEO to Present Invited Talk at Veterinary Surgery Meeting 2
(Date:7/30/2014)... Sciences Institute (SALSI), a joint venture between The University ... of Texas Health Science Center at San Antonio, has ... The winners, Emily Boice from UTSA and Lei Huang ... their project titled, "Novel engineered ferritins for tracking and ... and Huang,s research is focused on finding a treatment ...
(Date:7/30/2014)... associate professor Andrew S. Mount, performed cutting-edge research on ... novel anti-fouling paint for ships and boats and also ... team,s findings, published in Nature Communications ... attaches to a wide variety of surfaces using highly ... underwater heavy-duty adhesive. , "In previous research, we were ...
(Date:7/30/2014)... pests, shrinking ranges and a changing climate threaten ... important plants, and so conservationists establish seed collections ... gardens in hopes of preserving some genetic diversity., ... by simple models that offer a one-size-fits-all approach ... recommending saving 50 seed samples regardless of species, ...
Breaking Biology News(10 mins):Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2Saving seeds the right way can save the world's plants 2
... researchers are part of a nationwide team preparing to open ... genome of the single living sister species to all other ... a large shrub found only on the South Pacific island ... diversified over time and provide insight into the key processes ...
... The Ohio State University and Ohio Supercomputer Center ... develop a computer tool that researchers, government leaders and ... in energy-related technology, policy and pricing. Researchers will ... for Energy Pricing and Policy (ICS-EPP), which models the ...
... PHILADELPHIA The American Association for Cancer Research congratulates 12 ... Medicine. They are among the 65 new members and five ... the fields of health and medicine, the award recognizes individuals ... in the fields of health and medicine. "This ...
Cached Biology News:UF to help sequence genome of flowering plants' ancient living relative 2UF to help sequence genome of flowering plants' ancient living relative 3NSF grant to study national energy policy and technology impacts 2The AACR congratulates its members elected to the Institute of Medicine 2
... thermal cycler is a compact instrument for gene ... tubes, 12 x 0.5 ml tubes, or a ... a thumbwheel to adjust height and pressure to ... heat pumps provide excellent thermal performance, and the ...
MiniCycler thermal cycler with Hot Bonnet heated lid, holds 25x0.2ml tubes...
... with SR-101 Labeled Substrates (red fluorescence; ... measure serine protease activation • No ... FLISP Kits utilize cell-permeable, fluorescently labeled ... measure chymotrypsin-like activity in whole living ...
... MitoPT kit is used in conjunction with your ... and induce apoptosis according to your existing procedure ... a negative control). Once you have induced apoptosis ... to each population and incubate the cells for ...
Biology Products: